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Abstract
Purpose To evaluate the impact of age on treatment-
related acute morbidity, on modiWcations of drug doses and
radiotherapy and on disease-free and overall survival in
non-elderly and elderly with high-risk cervical cancer
treated with concurrent radiochemotherapy following lapa-
roscopic surgery.
Methods One hundred and two patients with high-risk
FIGO I – IVA cervical cancer (77 non-elderly [<60 years]
and 25 elderly [¸60 years]) were treated by radical hyster-
ectomy with lymphadenectomy (n = 91) and postoperative
radiochemotherapy or radical radiochemotherapy alone
after laparoscopic lymph node dissection (n = 11) patients
received Wve to six cycles of cis-platin, 40 mg/sqm weekly,
given concurrently to pelvic radiotherapy of 45–50.4 Gy in
5–6 weeks. Paraaortic radiotherapy with 45 Gy was per-
formed when laparoscopic staging revealed paraaortic node
metastases. Acute morbidity was prospectively scored
weekly. Toxicity-related protocol violations (treatment
breaks or dose reduction) were related with age, 5-year
overall survival (OS) and progression-free survival (PFS)
rates.
Results Clinical stages and histologic subtypes were
equally distributed. Grade 3/4 leukopenia, anemia, diarrhea
and nausea occurred more frequently in the elderly. 16
(22%) non-elderly and 6 (25%) elderly needed a modiWca-
tion of drug dose. 10/77 (13%) non-elderly patients and 11/25
(44%) of the elderly needed an unscheduled treatment
break (p = 0.002). OS and PFS were not diVerent between
age groups. The 5-year OS rate was 47 § 6% for non-elderly
patients and 45 § 10% for the elderly. Patients with/with-
out treatment breaks had a 5-year OS rate of 39 § 11%/
48 § 6%. The 5-year PFS rate is 49 § 6% for non-elderly
patients and 47 § 11% for the elderly. Patients with/
without treatment breaks had a 5-year PFS probability of
50 § 12%/48 § 6%. FIGO stage retains its prognostic
signiWcance irrespective of age.
Conclusions Concurrent radiochemotherapy caused slightly
higher acute toxicity with increasing age. Adjustment of
treatment intensity was more frequent in the elderly but did
not result in detrimental outcome Wgures.
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Introduction
A combination of surgery, radiotherapy and chemotherapy
has become a mainstay treatment for high-risk invasive car-
cinoma of the uterine cervix, since increased survival after
multimodal therapy compared to surgery or radiotherapy
alone has been reported in randomized studies in the late
90s (Morris et al. 1999; Rose et al. 1999; Green et al.
2001). Since the recommendation of The National Cancer
Institute of the United States of America to consider cis-
platinum containing chemotherapy to be given in addition
to radiotherapy in 1999 (McNeil 1999), new strategies and
surgical techniques have been introduced for dissection of
pelvic and paraaortic lymph nodes which result in an
improved pathologic staging (Altgassen et al. 2000; Köhler
et al.  2004). Likewise, new radiation technologies have
recently emerged such as three-dimensional conformal
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radiotherapy and intensity modulated radiotherapy, both
allowing for reduced exposure of normal tissues (Ahamad
et al. 2005; Vandecasteele et al. 2009).
Simultaneous radiochemotherapy has shown to increase
hematologic and gastrointestinal toxicity that may compro-
mise patients’ compliance in patients receiving adjuvant
radiochemotherapy due to risk factors (Peters et al. 2000).
The new surgical and radiotherapeutic strategies and tech-
niques however also harbor a speciWc proWle of adverse
eVects which may contribute speciWcally to modiWed treat-
ment-related morbidity. Systematic lymph node dissection
will result in increased subacute and late toxicity like infec-
tion, lymphoceles and chronic lymph edema of the lower
extremities particularly when more than 25 nodes have
been removed (Füller et al. 2008).
At the Jena University Hospital in the late 1990s, sys-
tematic pelvic and paraaortic laparoscopic lymph node dis-
section and radiochemotherapy irrespective of age has been
adopted for high-risk invasive cancer of the uterine cervix
as a routine method. A signiWcant proportion of patients are
elderly. Little has been reported on toxicity and morbidity
of multimodal treatment concepts including invasive lapa-
roscopic staging with special attention to age. We per-
formed a retrospective analysis of elderly deWned as
60 years and over at treatment start and non-elderly patients
diagnosed with high-risk carcinoma of the uterine cervix
with respect of treatment intensity, acute morbidity and
treatment outcome. To ascertain as much treatment homo-
geneity as possible only patients were included with their
surgery and radiochemotherapy carried out at the Depart-
ments of Gynecology and Radiation Oncology of the Jena
University Hospital.
Patients and methods
From the University Hospital Tumor Registry and from the
Local Area Network Treatment and Information System
(LANTIS) of the Dept. Radiation Oncology a list of all
patients treated for cervical carcinoma at the University
Hospital between 1/1999 and 12/2007 has been compiled.
Consecutively treated women were included in this analysis
if they have received postoperative radiochemotherapy due
to at least one risk factor or if they were considered inoper-
able due to local primary extension and/or extensive para-
aortic lymph node metastases or comorbidity. Risk factors
in their postoperative pathology report were considered
stage pT1b2 or higher, histologically proven lymph node
metastases, lymphatic vessel involvement and close margin
resection, deep stromal invasion, adenosquamous cell car-
cinoma or adenocarcinoma and parametrial involvement.
Patients not eligible for radical surgery of the primary or
with a pelvic recurrence after surgery alone were treated by
radical external beam radiotherapy and brachytherapy and
concurrently given chemotherapy. None had preoperative
radiotherapy or radiochemotherapy. When staging proce-
dures revealed distant metastases patients were excluded
from this analysis. One hundred and two patients met these
criteria and form the basis for this retrospective analysis.
Surgery
For surgical treatment of the cervical carcinoma, radical
hysterectomy was performed as laparoscopic assisted radi-
cal vaginal hysterectomy (LARVH) until 12/2005, later as
vaginal assisted laparoscopic radical hysterectomy
(VALRH). All patients received systematic laparoscopic
pelvic and paraaortic lymph node dissection and histopa-
thological staging.
Radiotherapy
All patients received external radiation treatment. Irradiated
volume was conWned to the pelvis (encompassing the pre-
sacral and pelvic lymph nodes, the upper vagina and the
cervical tumor if surgery has not been performed) only
when paraaortic nodes specimen revealed no metastasic
deposits at microscopic examination. In patients with
proven paraaortic lymph node metastases, the irradiated
volume included the pelvis and paraaortic nodes up to the
level Th 12 treated in a sequential manner. When paraaortic
irradiation was indicated, it was started after a break of
1–3 weeks after completion of pelvic radiotherapy.
Total external beam radiation dose of the pelvis was
45–50.4 Gy (5 £ 1.8 Gy/week prescribed to the 100% Isodose
and the 95% Isodose encompassing the aforementioned
volume) utilizing computerized tomography–based treat-
ment planning. During the initial period, a conformal four
Weld box was used. Recently, intensity modulated radio-
therapy using a step and shoot technology has become an
institutional standard technique to treat the pelvis. In cases
of marginal tumor resection, patients received an additional
external beam boost dose conWned to iliac nodes/lateral pel-
vic wall to 50.4 Gy. When indicated the paraaortic nodes
were treated by external beam conformal four Weld box
technique with a total dose of 45 Gy (5 £ 1.8 Gy/week).
All irradiations were performed with 15-MV photons.
External beam radiation was followed by intracavitary
brachytherapy by high-dose rate remote afterloading tech-
nique using 192- Iridium as radioactive source or an alterna-
tive form of boost. After hysterectomy, the boost dose was
given with two or three brachytherapy fractions 5–7 Gy each
at 5 mm tissue depth to the vaginal vault spaced by 1 week.
In patients retaining their uterus, a total dose of 35–40 Gy
to point A (International Commission on Radiation Units
and Measurements Report 62) was prescribed using Wve toJ Cancer Res Clin Oncol (2011) 137:481–488 483
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seven (median 6) insertions of a uterine applicator using
high-dose remote afterloading with 192-Iridium as radioac-
tive source. None had interstitial implants. In cases where a
cervical insertion was not successful, the boost was given
by reduced external four Weld box technique.
Concomitant chemotherapy
Pretreatment investigations
Patients were eligible for cis-platinum containing treatment
protocol if the renal function measured by the tubular
secretion of 99 m-Tc-mercaptoacetyltriglycin (MAG-3)
was normal (clearance minimum: 188 ml/min/1.73 sqm body
surface area [BSA]) and audiometry did not reveal severe
hypacusis (deWned as a loss of ¸25 dB or hypacusis at
8,000 Hz or greater). In patients with reduced MAG-3
clearance or with severe hypacusis diagnosed before start
of therapy the dose of cis-platinum was reduced appropri-
ately or was substituted by vinorelbine. Eligibility criteria
included normal blood cell count including absolute neutro-
phil count of 2 G/l or more, normal hemoglobin, normal
serum liver enzymes and electrolytes as well as normal
renal function parameters including creatinine clearance,
and an ECOG performance status of 0–2.
Treatment schedules
All radiochemotherapy courses have been administered on
an inpatient basis. Chemotherapy was given simultaneously
external beam radiotherapy of the pelvis only. During para-
aortic radiotherapy, chemotherapy has not been given.
Basically two types of chemotherapy protocols have been
applied in this cohort. At the beginning of the period,
reported Wve patients received a combination of cis-platinum
with 5-Xuorouracil (5-FU) according to the department’s
guidelines. These patients received 5-Xuorouracil, 1.5 g
absolute dose/24 h over 96 h as continuous infusion starting
on days 1 and 29 and cis-platinum, 20 mg/sqm BSA as a
2 h infusion on days 1–5 and 29–33 of pelvic radiotherapy.
The number of cycles scheduled was 2. All subsequent
patients were eligible to a protocol scheduling cis-platinum
once a week at a dose of 40 mg/sqm BSA given as a 2 h i.v.
infusion. Hydration with 2 liters normotone saline i.v. and
furosemide 24 h before and 24 h after end of cis-platinum
administration was obligatory. Patients with impaired renal
function and/or mild hypacusis or other ineligibilities for
full dose cis-platinum started their therapy with cis-platinum,
30 or 20 mg/sqm BSA weekly. In patients with contraindi-
cations against cis-platinum vinorelbine 20 mg/sqm BSA
was given instead orally once a week. The scheduled num-
ber of cycles was 5 or 6 depending on the total irradiation
time elapsed.
All patients had routine blood cell counts including
neutrophils once a week and additional counts when
indicated. Adverse eVects were prospectively documented
on a daily basis and their severity was classiWed according
to the common toxicity criteria (NIH 1998). The highest
grade of every type of adverse eVects was used for this
analysis. Drug dose delivered at each cycle was modiWed
when during radiochemotherapy one of the following toxic-
ities grade 2 or higher occurred: leukocyte count, anemia,
emesis, thrombopenia or diarrhea. When anemia grade 3
occurred (transfusion indicated) administration of cis-platinum
was terminated.
Follow-up and statistics
All women have been followed up at regularly intervals
mainly at the Department of Gynecology and Obstetrics of
the University Hospital until 12/2009 or at the date of their
death, except for two patients. These two were younger
than 60 years returned to their home country outside
Germany after therapy has been completed. Data of local
control status, distant metastasis status and overall survival
status were supplied by the Tumor Registry. This analysis
was focused on the comparison between age groups of non-
elderly (<60 years) and elderly (¸60 years) patients with
respect of acute toxicity, progression free and overall sur-
vival. Survival curves were estimated by the Kaplan–Meier
method. Comparison of survival probabilities were ana-
lyzed using the log-rank test. All statistical tests were two
sided and carried out at the 5% level of signiWcance.
Results
Table 1 provides patients’ demographic and treatment
characteristics. Median age at start of treatment was 47.7
(23–84) years, 25 women of them being 60 years or older.
Median follow-up time for all patients was 34.5 (4–109)
months and for surviving patients 59 (27–109) months. One
non-elderly patient died from unknown cause of death. One
elderly patient died from breast cancer.
Clinical stage of disease revealed an equal distribution
across the age cohorts (p = 0.936). Likewise the distribu-
tion of the histological tumor type (squamous carcinoma,
adenocarcinoma, adenosquamous carcinoma) is equal
across both age groups (p = 0.552). The frequence of node
positive tumors was high in both groups (58% in the
younger group vs. 48% in the elderly; Table 1).
Seven non-elderly and 4 elderly had no surgical removal
of the primary. Twenty-six non-elderly and 9 elderly
patients did not receive brachytherapy, either because of
refusal or due to complicating medical conditions that
precluded applicator placement.484 J Cancer Res Clin Oncol (2011) 137:481–488
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Acute toxicity
All patients were assessable for acute toxicity. In Table 2,
all adverse eVects in correlation to age cohorts are shown.
The majority of adverse reactions encountered were mild
(grades 1 or 2).Of 102 patients, 38 experienced any kind of
grade 3 or 4 toxicity, mainly hematologic and gastrointesti-
nal. The most frequent adverse eVects observed were hema-
tologic. Any grade of thrombocytopenia occurred more
frequently in the elderly (26 vs. 48%, p = 0.004). Grade 3
and 4 leukopenia, anemia, diarrhea and nausea were more
frequent in the elderly (Table 2). All other acute morbidi-
ties listed occurred with comparable frequency in the two
age groups. No toxic death (grade 5) occurred.
Chemotherapy, modiWcation of treatment intensity
Two non-elderly were excluded from any chemotherapy
due to severe co-morbidities and renal insuYciency. Data
upon drug dose reduction performed were not fully retriev-
able in four (three non-elderly, one elderly) patients. From
the remaining 96 patients, 56 (60%) received the drug regi-
men without any modiWcation. Forty (40%) patients needed
either any kind of drug dose reduction or an unscheduled
treatment break due to acute adverse eVects irrespective of
the schedule applied. The need for reduced drug dose in
any cycle due of the adverse eVects did not diVer between
the age groups (p = 0.690). 16 (22%) non-elderly and 6
(25%) elderly needed a modiWcation of the scheduled drug
dose. However, the frequency of unscheduled breaks of
their treatment due to acute morbidity was signiWcantly age
dependent (p = 0.002). 10 out of 77 (13%) non-elderly
Table 1 Patients’ demographic and treatment characteristics
(n = 102)
Non-elderly 
patients 
(n =7 7 )
Elderly patients
(n =2 5 )
Median age (range) 44 (23–59) 67 (60–84)
Tumor stage (FIGO) n (%) n (%)
I 30 (39%) 10 (40%)
II 24 (31%) 8 (32%)
III 13 (17%) 3 (12%)
IV 10 (13%) 4 (16%)
Node negative 32 (42%) 13 (52%)
Node positive 45 (58%) 12 (48%)
Histology
Squamous 63 (82%) 20 (80%)
Adenocarcinoma 7 (9%) 1 (4%)
Adenosquamous 
carcinoma
2 (3%) 2 (8%)
Other 5 (6%) 2 (8%)
Surgery: hysterectomy
Yes 70 (91%) 21 (84%)
No 7 (9%) 4 (16%)
Chemotherapy regimen
Dosagea
Cis-platinum 40 mg 69 21
Cis-platinum 30 mg 1 0
Cis-platinum 20 mg 1 1
Cis-platinum 20 mg +
5-FU 600 mg
20
Cis-platinum 20 mg +
5-FU 1,000 mg
21
Vinorelbine 20 mg 0 2
No chemotherapy 2 0
Number of cycles given
11 2
25 2
32 2
44 3
54 2 1 1
61 7 4
10b 10
No data 3 1
Radiotherapy pelvis
Total dose: mean 
(range; Gy)
44.6 (39.6–46.2) 44.6 (39.6–45.0)
<45 Gy 9 2
45 Gy 67 23
>45 Gy 1 0
Radiotherapy of paraaortic nodes performed
Yes 20 5
No 57 20
Table 1 continued
a All drug doses per sqm BSA
b On an individual base due to persistent disease
c Brachytherapy performed by 192-Iridium high-dose rate intracavi-
tary radiation
d 2 cases lost (non-elderly), in 4 no data upon dose reduction (3 non-
elderly, 1 elderly)
NS not signiWcant
Non-elderly 
patients 
(n =7 7 )
Elderly patients
(n =2 5 )
Brachytherapy performedc
Yes 51 16
No 26 9
Pelvic recurrenced
No 56 (75%) 15 (60%)
Yes 19 (25%) 10 (40%)J Cancer Res Clin Oncol (2011) 137:481–488 485
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patients and 11 out of 25 (44%) of the elderly needed a
treatment interruption.
Non-elderly (69) and elderly (21) patients scheduled for
40 mg/sqm BSA cis-platinum received a median cumula-
tive dose of 190 mg/sqm BSA and 173 mg/sqm BSA,
respectively. 42/69 non-elderly patients scheduled for
40 mg/sqm BSA cis-platinum received 5 cycles and 16
receive 6 cycles. Nine out of twenty-one non-elderly
patients scheduled for 40 mg/sqm BSA cis-platinum
received 5 cycles and 4 received 6 cycles (Fig. 1).
Recurrence
Pelvic recurrence and distant metastases were observed in
36 non-elderly (48%) and 12 elderly patients (48%). The
frequency of relapses was not related with modiWcation of
the scheduled therapy (non-elderly: p = 0.152; elderly:
p = 0.428). Pelvic recurrence were observed in 19 (25%)
non-elderly and 10 (40%) elderly patients. 8 (32%) of the
non-elderly patients and 5 (50%) of the elderly patients
needed a modiWcation of the scheduled therapy (p =n o t
signiWcant). Pulmonary metastases were observed in six,
Table 2 Incidence of the high-
est grade of acute adverse eVects 
(CTC-ClassiWcation [NIH]) 
observed during treatment 
according to age
EVect Highest grade of adverse 
eVect non-elderly (n =7 7 )
Highest grade of adverse 
eVect elderly (n =2 5 )
1/2
n (%)
3/4
n (%)
1/2
n (%)
3/4
n (%)
Leukopenia 43 (56) 21 (27) 10 (40) 8 (32)
Anemia 29 (38) 2 (3) 7 (28) 1 (4)
Diarrhea 26 (34) 1 (1) 8 (32) 1 (4)
Nausea 24 (31) 1 (1) 10 (40) 1 (4)
Thrombopenia 20 (26) 0 12 (48) 0
Skin hyperpigmentation 11 (14) 0 2 (8) 0
Epitheliolysis 10 (13) 0 2 (8) 0
Erythema 8 (10) 0 5 (20) 0
Creatinine clearance below 
lower normal limit
7 (9) 0 1 (4) 0
Emesis 7 (9) 0 4 (16) 0
Constipation 5 (6) 0 1 (4) 0
ALT increasea 5 (6) 0 0 0
AST increaseb 3 (4) 0 0 0
Hypocalcemia 3 (4) 0 1 (4) 0
Loss of appetite 3 (4) 0 1 (4) 0
Creatinine increase 2 (3) 0 0 0
Cystitis 2 (3) 0 0 0
Hypokalemia 2 (3) 0 0 0
Pruritus 2 (3) 0 0 0
Seizure 1 (1) 1 (1) 0 0
Enteritis 1 (1) 0 0 0
Fever 1 (1) 0 0 0
Dizziness 0 0 1 (4) 0
Smell alteration 0 0 1 (4) 0
Taste alteration 0 0 1 (4) 0
a ALT alaninaminotransferase, 
above upper normal limit
b AST aspartataminotransfer-
ase, above upper normal limit
Fig. 1 Frequency of weekly cycles of cis-platinum, 40 mg/sqm BSA
given in non-elderly and elderly patients
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bone metastases in Wve, hepatic metastases in three and
lymph node metastasis in three non-elderly patients. In the
elderly in two cases pulmonary metastases were encoun-
tered.
Overall and progression-free survival
Five-year overall survival for the entire group was 46 § 5%
(median: 46 months) and has not been found inXuenced by
age or treatment breaks (age: p = 0.882; treatment breaks:
p = 0.859). The 5-year overall survival rate is 47 § 6% for
non-elderly patients and 45 § 10% for the elderly (Fig. 2).
The 5-year overall survival rate is 39 § 11%/51 § 6%
(p = 0.759) in patients with/without treatment breaks. The
median survival is 46/35 months in patients with/without
treatment breaks. Overall survival at 5 years however was
inXuenced by the FIGO stage (p = 0.036). The 5-year over-
all survival rate is 53 § 6% for patients with FIGO I-II and
30 § 8% for patients with FIGO III-IV. The median sur-
vival is 32 months for the patients with FIGO III-IV.
5-year progression-free survival for the entire group was
48 § 5%, (median progression-free survival: 41 months).
Also progression-free survival was found independent from
age or treatment breaks (age: p = 0.963; treatment breaks:
p = 0.492). The 5-year progression-free survival rate is
49 § 6% for non-elderly patients and 47 § 11% for elderly
(Fig. 3). Median progression-free survival time is 43 versus
41 months in the non-elderly and the elderly, respectively.
Patients with/without treatment breaks had a 5-year
progression-free survival rate of 50 § 12%/48 § 6%. The
5-year progression-free survival depends on FIGO stage
(p = 0.036). The 5-year progression-free survival rate is
56 § 6% for patients with FIGO I-II and 30 § 9% for
patients with FIGO III-IV (Fig. 4). The median progres-
sion-free survival is 21 months for the patients with FIGO
III-IV.
Discussion
In the eastern part of Germany including the catchment area
of this study, the epidemiological data show an incidence of
cervical cancer with a high peak at 50.5 years and a second
lower peak beyond 65 years. Many factors may have
Fig. 2 Overall survival according to age at diagnosis in 102 patients
with high-risk cervical cancer
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0,4
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Fig. 3 Progression-free survival according to age at diagnosis in 102
patients with high-risk cervical cancer
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Fig. 4 Progression-free survival according to FIGO stage at diagnosis
in 102 patients with high-risk cervical cancer
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contributed to halved mortality observed between 1990 and
2005 (Stabenow et al. 2009). However, age has been identi-
Wed as adverse prognostic factor in some studies (Brun
et al. 2003, Croker et al. 2009; Wright et al. 2005), while in
others not (Kunos et al. 2009; Metindir and Bilir 2007;
Mitchell et al. 1998). If age is associated with worse prog-
nosis due to diVerent reasons, this would also change the
observed evolution of mortality in a senescent population in
the future. To continue the downward trend of cervical can-
cer mortality it will be crucial to improve outcome in the
elderly. The results obtained shed light upon the practica-
bility of an intensiWed treatment protocol also in the aged.
One explanation for unfavorable prognosis might be the
elderly present with more advanced tumor stages as shown
in previous studies (Brun et al. 2003). In the present study,
however, the elderly did neither present with more
advanced tumor stages nor with a higher rate of prognosti-
cally unfavorable adenocarcinoma which agrees with other
reports (Goodheart et al. 2008; Mitchell et al. 1998). In this
series, both age cohorts revealed node metastases in 50–60%
of all patients which is much higher than in other reports
(Rose et al. 1999; Eifel et al. 2004) and will have contrib-
uted to the unfavorable overall survival. Another reason for
decreasing survival with increasing age may be an impaired
tolerance of aggressive multimodal treatment protocols
(Kirwan et al. 2003) or omission of simultaneously given
chemotherapy at all in a subset of the elderly deemed not
eligible for chemoradiation (Goodheart et al. 2008). How-
ever, radiotherapy alone neither postoperatively nor as the
primary therapy is any longer the standard of care for high-
risk cervical cancer even when very sophisticated tech-
niques are used (Dimopoulos et al. 2009).
The accrual period of this analysis begun purposely
after the NCI clinical announcement has recommended
integrating cis-platinum to a standard radiotherapy proto-
col (McNeil 1999). Since the end of 1999 weekly cis-plat-
inum doses given concurrently to pelvic radiotherapy has
been adopted for postoperatively treated high-risk
patients, for patients with inoperable tumors and for those
medically unWt for surgery of the primary. Especially cis-
platinum compounds given concomitantly to postopera-
tive radiation therapy will lead to an increased overall
survival as shown in a metaanalysis (Green et al. 2001;
Anonymus 2008). At the same time, laparoscopic pelvic
and retroperitoneal lymphadenectomy had become an
internal standard procedure for all patients with cervical
cancer irrespective of the management of the primary and
of the patients’ age at our Department of Gynecology and
Obstetrics (Altgassen et al. 2000). Both changes in clini-
cal practice undoubtedly alter the proWle and intensity of
treatment-induced morbidity.
In this study, all patients with an ECOG index of 0-2
irrespective of age were scheduled for the same chemother-
apy protocol. Therefore, we should be able to determine
age-related diVerences in terms of treatment-related mor-
bidity and its impact on feasibility of an aggressive radio-
chemotherapy protocol in the elderly. Radiotherapy and
cis-platinum have an overlapping toxicity proWle. There-
fore, when chemotherapy is given to pelvic radiotherapy
their speciWc toxicities will add or potentate in part. Drug-
related hematological morbidity will be aggravated by
exposure of large volumes of bone marrow to X-rays par-
ticularly in pelvic radiotherapy leading to acute and even
chronic hematopoietic depression. In this series, severe
acute hematological morbidity was found more frequent in
the elderly, which is a common Wnding with diVerent drug
regimes (Peters et al. 2000). This has been anticipated since
bone marrow is less likely to recover from chemotherapy in
the elderly. New radiotherapy technologies may not alter
this toxicity, since intensity-modulated radiotherapy is opti-
mized essentially for small bowel and not pelvic bones’
sparing.
Although age is not a contraindication for radical radio-
therapy for pelvic tumors (Dimopoulos et al. 2009; Pignon
et al. 1997) bowel derived toxicity has been reported to
increase with age in patients receiving radiotherapy alone
(Huscher et al. 2009). When pelvic irradiation given alone
to patients 70 years and over in 29% unscheduled
treatment breaks were unavoidable due to acute toxicity
(Lindegaard et al. 2000). Similar Wgures have been
reported after external radiation combined with three frac-
tions of low-dose-rate brachytherapy without concurrent
chemotherapy (Sakurai et al. 2000; Minagawa et al. 1997).
These  Wgures were comparable to the presented data
despite chemotherapy have been added. This might be
attributed to irradiation technology, e.g. using high-energy
photons (15 MV) substituting cobalt X-rays and probably
more important the use of bowel sparing intensity modu-
lated radiotherapy.
Close clinical and laboratory monitoring has proven
essential when aggressive radiochemotherapy is given to
the elderly. We observed signiWcantly more treatment
breaks due to acute morbidity breaks which may be attrib-
uted to not sorting out patients deemed not suitable for this
intensive protocol before start. Others found no diVerences
in complication rates between younger and older women
but emphasize not all of the elderly have been treated by
chemotherapy (Goodheart et al. 2008). However, similar to
our Wndings in the elderly drug dose reduction during radio-
chemotherapy was not more frequent compared to younger
patients treated with the same protocol (Kunos et al. 2009).
In conclusion, our data demonstrate elderly patients
tolerate radiochemotherapy worse than younger patients.
Elderly may be treated safely with aggressive multimodal
protocols but demand for more intensive monitoring in
order to change treatment protocol early due to acute488 J Cancer Res Clin Oncol (2011) 137:481–488
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morbidity. However, signiWcantly more treatment breaks
do not compromise overall and progression-free survival.
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